ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-22 15:08:00,2022-04-22T15:08:00-04:00,2022-04-22,"ROSEN, A TOP RANKED LAW FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - April 22, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...",newsfilecorp.com,https://www.newsfilecorp.com/release/121407/ROSEN-A-TOP-RANKED-LAW-FIRM-Encourages-AbbVie-Inc.-Investors-with-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-a-top-ranked-law-firm-encourages-abbvie-inc-20220422.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-22 16:33:13,2022-04-22T16:33:13-04:00,2022-04-22,AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release,AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/1905635/abbvie-abbv-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release,https://images.financialmodelingprep.com/news/abbvie-abbv-earnings-expected-to-grow-what-to-know-20220422.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-22 17:15:00,2022-04-22T17:15:00-04:00,2022-04-22,"CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Shareholders of Securities Fraud Class Action Lawsuit","Radnor, Pennsylvania--(Newsfile Corp. - April 22, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/121375/CLASS-ACTION-NOTICE-Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc.-Shareholders-of-Securities-Fraud-Class-Action-Lawsuit?utm_source=snapi,https://images.financialmodelingprep.com/news/class-action-notice-kessler-topaz-meltzer-check-llp-reminds-20220422.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-23 06:08:00,2022-04-23T06:08:00-04:00,2022-04-23,3 Dividend Stocks You Can Buy and Hold for Decades,Each of these companies has a long history of success.,fool.com,https://www.fool.com/investing/2022/04/23/3-dividend-stocks-you-can-buy-and-hold-for-decades/,https://images.financialmodelingprep.com/news/3-dividend-stocks-you-can-buy-and-hold-for-20220423.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-23 15:10:00,2022-04-23T15:10:00-04:00,2022-04-23,"ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - April 23, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/121409/ROSEN-A-GLOBALLY-RECOGNIZED-FIRM-Encourages-AbbVie-Inc.-Investors-with-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-a-globally-recognized-firm-encourages-abbvie-inc-investors-20220423.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-24 05:00:00,2022-04-24T05:00:00-04:00,2022-04-24,3 Dividend Growth Titans to Increase Your Passive Income,There's nothing quite like a growing dividend to help you cover your costs when inflation rears its ugly head.,fool.com,https://www.fool.com/investing/2022/04/24/dividend-growth-titans-increase-passive-income/,https://images.financialmodelingprep.com/news/3-dividend-growth-titans-to-increase-your-passive-income-20220424.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-24 05:52:00,2022-04-24T05:52:00-04:00,2022-04-24,These Dividend Stocks Are Trouncing the Market -- Are They Still Buys?,Investors don't like these stocks only because of their dividends.,fool.com,https://www.fool.com/investing/2022/04/24/dividend-stocks-trouncing-the-market-are-they-buys/,https://images.financialmodelingprep.com/news/these-dividend-stocks-are-trouncing-the-market-are-they-20220424.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-25 05:52:00,2022-04-25T05:52:00-04:00,2022-04-25,3 Warren Buffett Dividend Stocks You Can Buy Right Now,They're not good picks just because of their dividends.,fool.com,https://www.fool.com/investing/2022/04/25/3-warren-buffett-dividend-stocks-you-can-buy-right/,https://images.financialmodelingprep.com/news/3-warren-buffett-dividend-stocks-you-can-buy-right-20220425.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-25 15:38:00,2022-04-25T15:38:00-04:00,2022-04-25,TOP RANKED ROSEN LAW FIRM Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV,"NEW YORK , April 25, 2022 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline. SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.",prnewswire.com,https://www.prnewswire.com/news-releases/top-ranked-rosen-law-firm-encourages-abbvie-inc-investors-with-losses-to-secure-counsel-before-important-deadline-in-securities-class-action--abbv-301532297.html,https://images.financialmodelingprep.com/news/top-ranked-rosen-law-firm-encourages-abbvie-inc-investors-20220425.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-26 06:30:18,2022-04-26T06:30:18-04:00,2022-04-26,What Stocks to Buy That Should Do Well in a Recession — Our 7 Top Picks,"Americans will still use brand names, buy groceries and clothes, get healthcare services and pay their utilities during a recession. That's good news for these 7 recession-resistant stocks to buy.",investorplace.com,https://investorplace.com/2022/04/recession-stocks-to-buy-that-will-do-well-in-a-recession-our-7-top-picks-mcd-tgt-wmt-pg-abbv-mgn-nrg/,https://images.financialmodelingprep.com/news/what-stocks-to-buy-that-should-do-well-in-20220426.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-26 07:36:17,2022-04-26T07:36:17-04:00,2022-04-26,7 Retirement Stocks to Buy to Sleep Soundly at Night,"As the population ages, more people are looking for ways to save for retirement. This can be done by investing in retirement stocks.",investorplace.com,https://investorplace.com/2022/04/7-retirement-stocks-to-buy-to-sleep-soundly-at-night-kmb-lmt-mrk-abbv-dlr-gis-pg/,https://images.financialmodelingprep.com/news/7-retirement-stocks-to-buy-to-sleep-soundly-at-20220426.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-26 10:30:00,2022-04-26T10:30:00-04:00,2022-04-26,"ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - April 26, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/121741/ROSEN-A-LEADING-INVESTOR-RIGHTS-LAW-FIRM-Encourages-AbbVie-Inc.-Investors-with-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-a-leading-investor-rights-law-firm-encourages-abbvie-20220426.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-26 11:04:00,2022-04-26T11:04:00-04:00,2022-04-26,"Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Securities Fraud Class Action Lawsuit","Radnor, Pennsylvania--(Newsfile Corp. - April 26, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/121743/Class-Action-Reminder-Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc.-Investors-of-Securities-Fraud-Class-Action-Lawsuit?utm_source=snapi,https://images.financialmodelingprep.com/news/class-action-reminder-kessler-topaz-meltzer-check-llp-reminds-20220426.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-26 12:47:19,2022-04-26T12:47:19-04:00,2022-04-26,Healthcare ETFs in Focus Ahead of Q1 Earnings,"The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.",zacks.com,https://www.zacks.com/stock/news/1907964/healthcare-etfs-in-focus-ahead-of-q1-earnings,https://images.financialmodelingprep.com/news/healthcare-etfs-in-focus-ahead-of-q1-earnings-20220426.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-27 08:35:00,2022-04-27T08:35:00-04:00,2022-04-27,AbbVie Stock: What To Know Ahead Of Upcoming Earnings,"AbbVie is set to report highly-anticipated earnings this week. The stock has been terrific this year, buoying many portfolios while other sectors have suffered.",seekingalpha.com,https://seekingalpha.com/article/4503783-abbvie-stock-what-to-know-upcoming-earnings,https://images.financialmodelingprep.com/news/abbvie-stock-what-to-know-ahead-of-upcoming-earnings-20220427.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-27 12:03:20,2022-04-27T12:03:20-04:00,2022-04-27,"Earnings Previews: AbbVie, AstraZeneca, Bristol-Meyers Squibb","Between the time markets closed on Tuesday and before they opened again on Wednesday, more than 600 U.S.",247wallst.com,https://247wallst.com/investing/2022/04/27/earnings-previews-abbvie-astrazeneca-bristol-meyers-squibb/,https://images.financialmodelingprep.com/news/earnings-previews-abbvie-astrazeneca-bristolmeyers-squibb-20220427.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-27 14:02:00,2022-04-27T14:02:00-04:00,2022-04-27,"INVESTOR NOTIFICATION: Kessler Topaz Meltzer & Check, LLP Announces Lead Plaintiff Deadline on June 6, 2022 in Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc.","RADNOR, Pa. , April 27, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period"").",prnewswire.com,https://www.prnewswire.com/news-releases/investor-notification-kessler-topaz-meltzer--check-llp-announces-lead-plaintiff-deadline-on-june-6-2022-in-securities-fraud-class-action-lawsuit-filed-against-abbvie-inc-301533292.html,https://images.financialmodelingprep.com/news/investor-notification-kessler-topaz-meltzer-check-llp-announces-lead-plaintiff-20220427.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-27 16:02:00,2022-04-27T16:02:00-04:00,2022-04-27,"ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - April 27, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/121901/ROSEN-A-LEADING-LAW-FIRM-Encourages-AbbVie-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-a-leading-law-firm-encourages-abbvie-inc-investors-20220427.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 07:15:16,2022-04-28T07:15:16-04:00,2022-04-28,7 ‘Strong Buy' Dividend Kings to Move to Fast in Case of Total Market Meltdown,"At 24/7 Wall St., we know how important dividend size, stability and growth are to growth and income investors who need a dependable stream of income.",247wallst.com,https://247wallst.com/investing/2022/04/28/7-strong-buy-dividend-kings-to-move-to-fast-in-case-of-total-market-meltdown/,https://images.financialmodelingprep.com/news/7-strong-buy-dividend-kings-to-move-to-fast-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 08:00:00,2022-04-28T08:00:00-04:00,2022-04-28,Abbvie and Plexium Enter Into Multi-Target Strategic Collaboration To Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions,"- Combines Plexium's novel TPD technology platform with AbbVie's extensive neuroscience expertise - SAN DIEGO , April 28, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This collaboration combines AbbVie's extensive neuroscience capabilities with Plexium's comprehensive TPD platform that enables the discovery of novel therapies toward historically challenging drug targets.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-and-plexium-enter-into-multi-target-strategic-collaboration-to-develop-and-commercialize-targeted-protein-degradation-therapies-for-neurological-conditions-301535250.html,https://images.financialmodelingprep.com/news/abbvie-and-plexium-enter-into-multitarget-strategic-collaboration-to-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 10:49:21,2022-04-28T10:49:21-04:00,2022-04-28,7 A-Rated Dividend Stocks to Buy Forever,"Whether in a bull market, bear market, or something in-between, make these seven high-quality dividend stocks long-term portfolio holdings. The post 7 A-Rated Dividend Stocks to Buy Forever appeared first on InvestorPlace.",investorplace.com,https://investorplace.com/2022/04/7-a-rated-dividend-stocks-to-buy-forever/,https://images.financialmodelingprep.com/news/7-arated-dividend-stocks-to-buy-forever-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 11:22:27,2022-04-28T11:22:27-04:00,2022-04-28,Why Earnings Season Could Be Great for AbbVie (ABBV),AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,zacks.com,https://www.zacks.com/stock/news/1910182/why-earnings-season-could-be-great-for-abbvie-abbv,https://images.financialmodelingprep.com/news/why-earnings-season-could-be-great-for-abbvie-abbv-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 12:02:09,2022-04-28T12:02:09-04:00,2022-04-28,"Drug/Biotech Stocks Q1 Earnings Due on Apr 29: BMY, ABBV, AZN","Let us take a look at what is in store for BMY, ABBV, and AZN that are scheduled to report on Apr 29.",zacks.com,https://www.zacks.com/stock/news/1910199/drug-biotech-stocks-q1-earnings-due-on-apr-29-bmy-abbv-azn,https://images.financialmodelingprep.com/news/drugbiotech-stocks-q1-earnings-due-on-apr-29-bmy-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 15:49:00,2022-04-28T15:49:00-04:00,2022-04-28,Many Big Pharma Stocks Have Outperformed. It Isn't Too Late to Buy.,The companies' earnings don't depend on the strength of the economy. Drug demand doesn't waver when consumers tighten their budgets.,barrons.com,https://www.barrons.com/articles/big-pharma-stocks-defensive-buy-51651175275,https://images.financialmodelingprep.com/news/many-big-pharma-stocks-have-outperformed-it-isnt-too-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-28 19:07:00,2022-04-28T19:07:00-04:00,2022-04-28,"Kessler Topaz Meltzer & Check, LLP - Important Reminder for AbbVie, Inc. Investors of Securities Fraud Class Action Lawsuit Filed on their Behalf","Radnor, Pennsylvania--(Newsfile Corp. - April 28, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/121745/Kessler-Topaz-Meltzer-Check-LLP-Important-Reminder-for-AbbVie-Inc.-Investors-of-Securities-Fraud-Class-Action-Lawsuit-Filed-on-their-Behalf?utm_source=snapi,https://images.financialmodelingprep.com/news/kessler-topaz-meltzer-check-llp-important-reminder-for-abbvie-20220428.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 07:43:00,2022-04-29T07:43:00-04:00,2022-04-29,AbbVie Reports First-Quarter 2022 Financial Results,"Reports First-Quarter Diluted EPS of $2.51 on a GAAP Basis, an Increase of 26.1 Percent; Adjusted Diluted EPS of $3.16, an Increase of 9.3 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense 1 Delivers First-Quarter Net Revenues of $13.538 Billion, an Increase of 4.1 Percent on a Reported Basis and 5.4 Percent Operationally First-Quarter Global Net Revenues from the Immunology Portfolio Were $6.141 Billion, an Increase of 6.9 Percent on a Reported Basis, or 8.1 Percent on an Operational Basis; U.S. Humira Net Revenues Were $3.993 Billion, an Increase of 2.2 Percent; Internationally, Humira Net Revenues Were $743 Million, a Decrease of 22.6 Percent on a Reported Basis, or 17.9 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $940 Million; Global Rinvoq Net Revenues Were $465 Million First-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.646 Billion, a Decrease of 1.6 Percent on a Reported Basis, or 0.6 Percent on an Operational Basis; Global Imbruvica Net Revenues Were $1.173 Billion, a Decrease of 7.4 Percent, with U.S. Net Revenues of $874 Million and International Profit Sharing of $299 Million; Global Venclexta Net Revenues Were $473 Million First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.488 Billion, an Increase of 19.2 Percent on a Reported Basis, or 20.4 Percent on an Operational Basis; Global Botox Therapeutic Net Revenues Were $614 Million; Vraylar Net Revenues Were $427 Million First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.374 Billion, an Increase of 20.5 Percent on a Reported Basis, or 22.5 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $641 Million; Global Juvederm Net Revenues Were $410 Million Updates 2022 Adjusted Diluted EPS Guidance Range from $14.00 - $14.20 to $13.92 - $14.12, which Includes an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Incurred During the First Quarter 2022 NORTH CHICAGO, Ill. , April 29, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-reports-first-quarter-2022-financial-results-301536204.html,https://images.financialmodelingprep.com/news/abbvie-reports-firstquarter-2022-financial-results-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 07:49:00,2022-04-29T07:49:00-04:00,2022-04-29,AbbVie misses quarterly sales estimates as Humira rivals bite,"AbbVie Inc missed Wall Street estimates for first-quarter sales on Friday, hurt by European competition for its blockbuster rheumatoid arthritis drug Humira and lower-than-expected revenue from its newer drug Rinvoq.",reuters.com,https://www.reuters.com/article/abbvie-results/abbvie-misses-quarterly-sales-estimates-as-humira-rivals-bite-idUSKCN2ML0YE,https://images.financialmodelingprep.com/news/abbvie-misses-quarterly-sales-estimates-as-humira-rivals-bite-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 08:07:11,2022-04-29T08:07:11-04:00,2022-04-29,AbbVie's stock is down 3% after missing on revenue in the first quarter of 2022,"Shares of AbbVie Inc. ABBV, -0.83% were down 3.4% in premarket trading on Friday after the company missed on revenue in the first quarter of the year. AbbVie had earnings of $4.5 billion, or $2.51 per share, in the first quarter of 2022, up from $3.5 billion, or $1.99 per share, in the same quarter of 2021.",marketwatch.com,https://www.marketwatch.com/story/abbvies-stock-is-down-3-after-missing-on-revenue-in-the-first-quarter-of-2022-2022-04-29,https://images.financialmodelingprep.com/news/abbvies-stock-is-down-3-after-missing-on-revenue-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 09:55:05,2022-04-29T09:55:05-04:00,2022-04-29,"AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance","AbbVie Inc (NYSE: ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion.",benzinga.com,https://www.benzinga.com/general/biotech/22/04/26895813/abbvie-shares-fall-on-mixed-bag-q1-results-cuts-fy22-profit-guidance,https://images.financialmodelingprep.com/news/abbvie-shares-fall-on-mixed-bag-q1-results-cuts-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 10:02:00,2022-04-29T10:02:00-04:00,2022-04-29,AbbVie Shares Drop Amid Missed Sales Expectations for Key Drugs,The company's mega-blockbuster Humira—used to treat rheumatoid arthritis—will face competition from so-called biosimilars in the U.S. next year.,barrons.com,https://www.barrons.com/articles/abbvie-stock-earnings-guidance-humira-arthritis-51651240769,https://images.financialmodelingprep.com/news/abbvie-shares-drop-amid-missed-sales-expectations-for-key-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 10:32:26,2022-04-29T10:32:26-04:00,2022-04-29,AbbVie (ABBV) Tops Q1 Earnings Estimates,"AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?",zacks.com,https://www.zacks.com/stock/news/1911511/abbvie-abbv-tops-q1-earnings-estimates,https://images.financialmodelingprep.com/news/abbvie-abbv-tops-q1-earnings-estimates-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 11:20:02,2022-04-29T11:20:02-04:00,2022-04-29,AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q1 2022 Results - Earnings Call Transcript,"AbbVie Inc. (NYSE:ABBV ) Q1 2022 Earnings Conference Call April 29, 2022 9:00 AM ET Company Participants Liz Shea - Vice President, Head of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Tom Hudson - Senior Vice President, R&D, & Chief Scientific Officer Rob Michael - Vice Chairman, Finance & Commercial Operations & Chief Financial Officer Carrie Strom - Senior Vice President and President, Global Allergan Aesthetics Neil Gallagher - Vice President and Chief Medical Officer Conference Call Participants Mohit Bansal - Wells Fargo Terence Flynn - Morgan Stanley Steve Scala - Cowen Andrew Baum - Citi Chris Schott - JPMorgan Chris Shibutani - Goldman Sachs Vamil Divan - Mizuho Securities Geoff Meacham - Bank of America Gary Nachman - BMO Capital Markets Robyn Karnauskas - Truist Securities Josh Schimmer - Evercore ISI Operator Good morning and thank you for standing by. Welcome to the AbbVie First Quarter 2022 Earnings Conference Call.",seekingalpha.com,https://seekingalpha.com/article/4505115-abbvie-inc-abbv-ceo-rick-gonzalez-on-q1-2022-results-earnings-call-transcript,https://images.financialmodelingprep.com/news/abbvie-inc-abbv-ceo-rick-gonzalez-on-q1-2022-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 12:29:33,2022-04-29T12:29:33-04:00,2022-04-29,A Trio of Stocks Beating the S&P 500,"Shareholders of Nokia Oyj ( NOK , Financial), AbbVie Inc. ( ABBV , Financial) and Microsoft Corp. ( MSFT , Financial) saw the value of their shares increase significantly over the past year, outperforming the S&P 500 Index. The benchmark index for the U.S. market stands at $4,287.50 as of April 28, having gained 1% over the past year.",gurufocus.com,https://www.gurufocus.com/news/1699463/a-trio-of-stocks-beating-the-sp-500,https://images.financialmodelingprep.com/news/a-trio-of-stocks-beating-the-sp-500-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 12:48:18,2022-04-29T12:48:18-04:00,2022-04-29,"AbbVie (ABBV) Q1 Earnings Top, Competition Rises for Imbruvica","AbbVie (ABBV) beats estimates for first-quarter 2022 earnings while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales.",zacks.com,https://www.zacks.com/stock/news/1912136/abbvie-abbv-q1-earnings-top-competition-rises-for-imbruvica,https://images.financialmodelingprep.com/news/abbvie-abbv-q1-earnings-top-competition-rises-for-imbruvica-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 14:44:00,2022-04-29T14:44:00-04:00,2022-04-29,RINVOQ® (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis,"Across the two pivotal trials, RINVOQ delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with RINVOQ versus 26% and 18.2% with placebo) at week 14 compared to placebo1 RINVOQ demonstrated significant improvement in signs and symptoms of AS at week 141-4 FDA approval in AS marks the fifth indication for RINVOQ in chronic immune-mediated diseases1 NORTH CHICAGO, Ill., April 29, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.1 ""Ankylosing spondylitis is a debilitating disease that often affects younger adults and, over time, can result in lasting structural damage that can take an emotional toll on a patient's life,"" said Thomas Hudson, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/rinvoq-upadacitinib-approved-by-us-fda-as-an-oral-treatment-for-adults-with-active-ankylosing-spondylitis-301536539.html,https://images.financialmodelingprep.com/news/rinvoq-upadacitinib-approved-by-us-fda-as-an-oral-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-29 16:46:30,2022-04-29T16:46:30-04:00,2022-04-29,Why AbbVie's Shares Dropped 10.5% Friday,Some of the pharmaceutical company's sales trends concerned investors.,fool.com,https://www.fool.com/investing/2022/04/29/why-abbvies-shares-dropped-105-friday/,https://images.financialmodelingprep.com/news/why-abbvies-shares-dropped-105-friday-20220429.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-30 05:57:00,2022-04-30T05:57:00-04:00,2022-04-30,AbbVie's Q1 Good News That Investors Could Be Missing,"The big drugmaker's results were disappointing, but there were several things to like in its report.",fool.com,https://www.fool.com/investing/2022/04/30/abbvies-q1-good-news-that-investors-could-be-missi/,https://images.financialmodelingprep.com/news/abbvies-q1-good-news-that-investors-could-be-missing-20220430.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-30 11:00:00,2022-04-30T11:00:00-04:00,2022-04-30,"Want $2,000 in Passive Income? Invest $10,000 in This Cathie Wood Dividend Stock and Wait 5 Years",This dividend stock is one of the few holdings that Cathie Wood and Warren Buffett have in common.,fool.com,https://www.fool.com/investing/2022/04/30/want-2000-passive-income-invest-10000-stock/,https://images.financialmodelingprep.com/news/want-2000-in-passive-income-invest-10000-in-this-20220430.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-04-30 16:32:58,2022-04-30T16:32:58-04:00,2022-04-30,AbbVie: Q122 Results Dampen Enthusiasm & Test Management's Growth Plans,"AbbVie reported Q122 earnings last night, and there was good and bad news - the bad led to a share price drop of ~10%. Revenues came in a little lower than Street expectations, at $13.54bn, and FY22 EPS was downgraded from $14.00 - $14.20 to $13.92 - $14.12.",seekingalpha.com,https://seekingalpha.com/article/4505567-abbvie-q122-results-dampen-enthusiasm-and-test-managements-growth-plans,https://images.financialmodelingprep.com/news/abbvie-q122-results-dampen-enthusiasm-test-managements-growth-plans-20220430.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-01 06:02:00,2022-05-01T06:02:00-04:00,2022-05-01,"ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - May 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/122248/ROSEN-RECOGNIZED-INVESTOR-COUNSEL-Encourages-AbbVie-Inc.-Investors-With-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-recognized-investor-counsel-encourages-abbvie-inc-investors-with-20220501.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-01 17:00:56,2022-05-01T17:00:56-04:00,2022-05-01,The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now,The Cannabis Industry And Parts Of The Sector To Watch In 2022 The post The Best Marijuana Stocks In 2022 And The Different Cannabis Sectors To Watch Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.,marijuanastocks.com,https://marijuanastocks.com/the-best-marijuana-stocks-in-2022-and-the-different-cannabis-sectors-to-watch-right-now/,https://images.financialmodelingprep.com/news/the-best-marijuana-stocks-in-2022-and-the-different-20220501.jpeg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-02 09:06:00,2022-05-02T09:06:00-04:00,2022-05-02,"Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for AbbVie, Inc. Investors in Securities Fraud Class Action Lawsuit","Radnor, Pennsylvania--(Newsfile Corp. - May 2, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/122179/Kessler-Topaz-Meltzer-Check-LLP-Important-Deadline-Reminder-for-AbbVie-Inc.-Investors-in-Securities-Fraud-Class-Action-Lawsuit?utm_source=snapi,https://images.financialmodelingprep.com/news/kessler-topaz-meltzer-check-llp-important-deadline-reminder-for-20220502.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-02 09:52:50,2022-05-02T09:52:50-04:00,2022-05-02,8 Dividend Aristocrat Leaders to Buy Now With the Stock Market Ready to Blow Up,"The writing is on the wall, and veteran investors know it. Any time you have an almost a 1,000 point move in the venerable Dow Jones industrial average and give it all back the next day like we did late last week, it indicates that fund managers are selling every uptick, and savvy hedge fund portfolio managers are trying to clear as much margin debt as possible.",247wallst.com,https://247wallst.com/investing/2022/05/02/8-dividend-aristocrat-leaders-to-buy-now-with-the-stock-market-ready-to-blow-up/,https://images.financialmodelingprep.com/news/8-dividend-aristocrat-leaders-to-buy-now-with-the-20220502.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-02 14:51:00,2022-05-02T14:51:00-04:00,2022-05-02,"Rosen, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","NEW YORK , May 2, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline. SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.",prnewswire.com,https://www.prnewswire.com/news-releases/rosen-a-leading-law-firm-encourages-abbvie-inc-investors-with-losses-exceeding-100k-to-secure-counsel-before-important-deadline-in-securities-class-action--abbv-301537460.html,https://images.financialmodelingprep.com/news/rosen-a-leading-law-firm-encourages-abbvie-inc-investors-20220502.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-03 13:16:00,2022-05-03T13:16:00-04:00,2022-05-03,"ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - May 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/122599/ROSEN-RESPECTED-INVESTOR-COUNSEL-Encourages-AbbVie-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-respected-investor-counsel-encourages-abbvie-inc-investors-to-20220503.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-04 05:52:00,2022-05-04T05:52:00-04:00,2022-05-04,"These Warren Buffett Dividend Stocks Can Make You $12,800 in Passive Income","You'll need to invest $100,000 in each stock to generate five-figure annual income.",fool.com,https://www.fool.com/investing/2022/05/04/warren-buffett-dividend-stocks-passive-income/,https://images.financialmodelingprep.com/news/these-warren-buffett-dividend-stocks-can-make-you-12800-20220504.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-05 05:52:00,2022-05-05T05:52:00-04:00,2022-05-05,This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better,The big biotech's winning ways are likely to continue.,fool.com,https://www.fool.com/investing/2022/05/05/this-stock-is-trouncing-the-market-in-2022-and-its/,https://images.financialmodelingprep.com/news/this-stock-is-trouncing-the-market-in-2022-and-20220505.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-05 13:52:00,2022-05-05T13:52:00-04:00,2022-05-05,ABBV LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of ABBVIE INC. Shareholders,"New York, New York--(Newsfile Corp. - May 5, 2022) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of AbbVie Inc. (NYSE: ABBV).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/abbvie-inc-loss-submission-form/?id=26860&from=5A",newsfilecorp.com,https://www.newsfilecorp.com/release/122949/ABBV-LAWSUIT-FILED-Jakubowitz-Law-Pursues-Claims-on-Behalf-of-ABBVIE-INC.-Shareholders?utm_source=snapi,https://images.financialmodelingprep.com/news/abbv-lawsuit-filed-jakubowitz-law-pursues-claims-on-behalf-20220505.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-05 20:01:00,2022-05-05T20:01:00-04:00,2022-05-05,"Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm","Radnor, Pennsylvania--(Newsfile Corp. - May 5, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/122662/Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc.-Investors-of-Important-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-and-Encourages-Investors-with-Substantial-Losses-to-Contact-the-Firm?utm_source=snapi,https://images.financialmodelingprep.com/news/kessler-topaz-meltzer-check-llp-reminds-abbvie-inc-investors-20220505.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-06 07:33:52,2022-05-06T07:33:52-04:00,2022-05-06,7 Defensive Dividend Healthcare Stocks to Buy Now,"As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.",investorplace.com,https://investorplace.com/2022/05/7-defensive-healthcare-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/7-defensive-dividend-healthcare-stocks-to-buy-now-20220506.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-06 09:05:00,2022-05-06T09:05:00-04:00,2022-05-06,"Shareholder Action Alert: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm","Los Angeles, California--(Newsfile Corp. - May 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. (""AbbVie"" or ""the Company"") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between April 30, 2021 and August 31, 2021, inclusive (the...",newsfilecorp.com,https://www.newsfilecorp.com/release/123035/Shareholder-Action-Alert-The-Schall-Law-Firm-Encourages-Investors-in-AbbVie-Inc.-with-Losses-of-100000-to-Contact-the-Firm?utm_source=snapi,https://images.financialmodelingprep.com/news/shareholder-action-alert-the-schall-law-firm-encourages-investors-20220506.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-06 16:04:00,2022-05-06T16:04:00-04:00,2022-05-06,"SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of AbbVie Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 6, 2022 - (ABBV)","New York, New York--(Newsfile Corp. - May 6, 2022) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of AbbVie Inc. (NYSE: ABBV).Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/abbvie-inc-loss-submission-form/?id=26938&from=5",newsfilecorp.com,https://www.newsfilecorp.com/release/123118/SHAREHOLDER-ALERT-The-Gross-Law-Firm-Notifies-Shareholders-of-AbbVie-Inc.-of-a-Class-Action-Lawsuit-and-a-Lead-Plaintiff-Deadline-of-June-6-2022-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-20220506.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-07 16:44:00,2022-05-07T16:44:00-04:00,2022-05-07,"Important June 6, 2022 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds AbbVie, Inc. Investors of Securities Fraud Class Action Lawsuit","Radnor, Pennsylvania--(Newsfile Corp. - May 7, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period"").CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK ON...",newsfilecorp.com,https://www.newsfilecorp.com/release/122663/Important-June-6-2022-Deadline-Reminder-Kessler-Topaz-Meltzer-Check-LLP-Reminds-AbbVie-Inc.-Investors-of-Securities-Fraud-Class-Action-Lawsuit?utm_source=snapi,https://images.financialmodelingprep.com/news/important-june-6-2022-deadline-reminder-kessler-topaz-meltzer-20220507.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-08 09:00:00,2022-05-08T09:00:00-04:00,2022-05-08,"AbbVie: Buy, Hold, Or Sell After Q1 Results?","AbbVie is a very high-quality company with strong cash flows, exactly the type of company you want to own if we fall into a recession. But it recently posted disappointing results that caused a selloff.",seekingalpha.com,https://seekingalpha.com/article/4507891-abbvie-buy-hold-or-sell-after-q1-results,https://images.financialmodelingprep.com/news/abbvie-buy-hold-or-sell-after-q1-results-20220508.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-09 08:56:00,2022-05-09T08:56:00-04:00,2022-05-09,"Shareholder Action Reminder: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm","Los Angeles, California--(Newsfile Corp. - May 9, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. (""AbbVie"" or ""the Company"") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.",newsfilecorp.com,https://www.newsfilecorp.com/release/123202/Shareholder-Action-Reminder-The-Schall-Law-Firm-Encourages-Investors-in-AbbVie-Inc.-with-Losses-of-100000-to-Contact-the-Firm?utm_source=snapi,https://images.financialmodelingprep.com/news/shareholder-action-reminder-the-schall-law-firm-encourages-investors-20220509.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-09 17:00:00,2022-05-09T17:00:00-04:00,2022-05-09,"AbbVie, Inc. Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Important Lead Plaintiff Deadline on June 6, 2022 in Securities Fraud Class Action Lawsuit","Radnor, Pennsylvania--(Newsfile Corp. - May 9, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/122664/AbbVie-Inc.-Deadline-Reminder-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Investors-of-Important-Lead-Plaintiff-Deadline-on-June-6-2022-in-Securities-Fraud-Class-Action-Lawsuit?utm_source=snapi,https://images.financialmodelingprep.com/news/abbvie-inc-deadline-reminder-kessler-topaz-meltzer-check-llp-20220509.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-09 18:15:00,2022-05-09T18:15:00-04:00,2022-05-09,"ABBV SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages AbbVie Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - May 9, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/123233/ABBV-SHAREHOLDER-ALERT-ROSEN-TRUSTED-NATIONAL-TRIAL-COUNSEL-Encourages-AbbVie-Inc.-Investors-with-Losses-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/abbv-shareholder-alert-rosen-trusted-national-trial-counsel-encourages-20220509.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-10 08:37:00,2022-05-10T08:37:00-04:00,2022-05-10,"Shareholder Action Notice: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm","Los Angeles, California--(Newsfile Corp. - May 10, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. (""AbbVie"" or ""the Company"") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.",newsfilecorp.com,https://www.newsfilecorp.com/release/123425/Shareholder-Action-Notice-The-Schall-Law-Firm-Encourages-Investors-in-AbbVie-Inc.-with-Losses-of-100000-to-Contact-the-Firm?utm_source=snapi,https://images.financialmodelingprep.com/news/shareholder-action-notice-the-schall-law-firm-encourages-investors-in-20220510.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-10 10:26:00,2022-05-10T10:26:00-04:00,2022-05-10,"ABBVIE INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against Abbvie, Inc. (ABBV); Lead Plaintiff Deadline is June 6, 2022","Philadelphia, Pennsylvania--(Newsfile Corp. - May 10, 2022) - Berger Montague is investigating securities fraud allegations on behalf of investors who purchased the securities of AbbVie, Inc. (""AbbVie"" or the ""Company"") (NYSE: ABBV) between April 30, 2021 and August 31, 2021 (the ""Class Period""). If you purchased AbbVie securities during the Class Period, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or...",newsfilecorp.com,https://www.newsfilecorp.com/release/123446/ABBVIE-INC.-Company-News-Berger-Montague-Investigates-Securities-Fraud-Allegations-Against-Abbvie-Inc.-ABBV-Lead-Plaintiff-Deadline-is-June-6-2022?utm_source=snapi,https://images.financialmodelingprep.com/news/abbvie-inc-company-news-berger-montague-investigates-securities-fraud-20220510.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 08:30:00,2022-05-12T08:30:00-04:00,2022-05-12,"AbbVie Awards 45 Scholarships to U.S. Students Living with Chronic, Immune-Mediated Diseases in Their Pursuit of Higher Education","Since 2016, the AbbVie Immunology Scholarship program has helped more than 300 students impacted by immune-mediated diseases across rheumatology, gastroenterology and dermatology NORTH CHICAGO, Ill. , May 12, 2022 /PRNewswire/ -- AbbVie today announced the 2022-2023 class of recipients of the AbbVie Immunology Scholarship, which provides financial support to students living with chronic, immune-mediated diseases pursuing higher education in the United States.",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-awards-45-scholarships-to-us-students-living-with-chronic-immune-mediated-diseases-in-their-pursuit-of-higher-education-301546056.html,https://images.financialmodelingprep.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 08:59:00,2022-05-12T08:59:00-04:00,2022-05-12,"Investor Action Alert: The Schall Law Firm Encourages Investors in AbbVie Inc. with Losses of $100,000 to Contact the Firm","Los Angeles, California--(Newsfile Corp. - May 12, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AbbVie Inc. (""AbbVie"" or ""the Company"") (NYSE: ABBV) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.",newsfilecorp.com,https://www.newsfilecorp.com/release/123775/Investor-Action-Alert-The-Schall-Law-Firm-Encourages-Investors-in-AbbVie-Inc.-with-Losses-of-100000-to-Contact-the-Firm?utm_source=snapi,https://images.financialmodelingprep.com/news/investor-action-alert-the-schall-law-firm-encourages-investors-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 11:39:00,2022-05-12T11:39:00-04:00,2022-05-12,AbbVie to Showcase Oncology Portfolio and Pipeline During the 2022 ASCO and EHA Annual Congresses,"AbbVie will present 46 abstracts for six investigational and approved medicines across eight cancer types A five-year update from the CLL14 Phase 3 VENCLYXTO®/VENCLEXTA® (venetoclax) and obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) will be presented at EHA Nine abstracts showing results from ongoing trials studying investigational epcoritamab will be presented at both meetings NORTH CHICAGO, Ill. , May 12, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present 46 abstracts across eight types of cancer during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and the European Hematology Association (EHA) Congress (June 9-17).",prnewswire.com,https://www.prnewswire.com/news-releases/abbvie-to-showcase-oncology-portfolio-and-pipeline-during-the-2022-asco-and-eha-annual-congresses-301546304.html,https://images.financialmodelingprep.com/news/abbvie-to-showcase-oncology-portfolio-and-pipeline-during-the-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 13:07:00,2022-05-12T13:07:00-04:00,2022-05-12,ABBV LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving AbbVie Inc,"New York, New York--(Newsfile Corp. - May 12, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased AbbVie Inc. (""AbbVie"") (NYSE: ABBV) between April 30, 2021 and August 31, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.https://www.wongesq.com/pslra-1/abbvie-inc-loss-submission-form-2?prid=27180&wire=5.",newsfilecorp.com,https://www.newsfilecorp.com/release/123826/ABBV-LAWSUIT-The-Law-Offices-of-Vincent-Wong-Notify-Investors-of-a-Class-Action-Lawsuit-Involving-AbbVie-Inc?utm_source=snapi,https://images.financialmodelingprep.com/news/abbv-lawsuit-the-law-offices-of-vincent-wong-notify-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 15:32:00,2022-05-12T15:32:00-04:00,2022-05-12,"AbbVie Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 6, 2022 to Discuss Your Rights - ABBV","New York, New York--(Newsfile Corp. - May 12, 2022) - Levi & Korsinsky, LLP notifies investors in AbbVie Inc. (""AbbVie"" or the ""Company"") (NYSE: ABBV) of a class action securities lawsuit.The lawsuit on behalf of AbbVie investors has been commenced in the the United States District Court for the Northern District of Illinois. Affected investors purchased or otherwise acquired certain AbbVie Inc. securities between April 30, 2021 and August 31, 2021. Follow the link below...",newsfilecorp.com,https://www.newsfilecorp.com/release/123854/AbbVie-Securities-Fraud-Class-Action-Lawsuit-Pending-Contact-Levi-Korsinsky-Before-June-6-2022-to-Discuss-Your-Rights-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/abbvie-securities-fraud-class-action-lawsuit-pending-contact-levi-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-12 15:48:03,2022-05-12T15:48:03-04:00,2022-05-12,AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals,AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.,zacks.com,https://www.zacks.com/stock/news/1923567/abbvie-s-abbv-rinvoq-meets-crohn-s-disease-study-goals,https://images.financialmodelingprep.com/news/abbvies-abbv-rinvoq-meets-crohns-disease-study-goals-20220512.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-13 05:52:00,2022-05-13T05:52:00-04:00,2022-05-13,3 Dividend Stocks You Can Buy and Hold for Decades,You can really think long term with these great dividend stocks.,fool.com,https://www.fool.com/investing/2022/05/13/3-dividend-stocks-you-can-buy-and-hold-for-decades/,https://images.financialmodelingprep.com/news/3-dividend-stocks-you-can-buy-and-hold-for-20220513.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-13 08:52:00,2022-05-13T08:52:00-04:00,2022-05-13,"ABBV INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against AbbVie, Inc.","Radnor, Pennsylvania--(Newsfile Corp. - May 13, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that the firm has filed a securities class action lawsuit against AbbVie, Inc. (AbbVie) (NYSE: ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie securities between April 30, 2021, and August 31, 2021, inclusive (the ""Class Period""). CLICK HERE TO SUBMIT YOUR ABBVIE LOSSES. YOU CAN ALSO CLICK...",newsfilecorp.com,https://www.newsfilecorp.com/release/123612/ABBV-INVESTOR-REMINDER-Kessler-Topaz-Meltzer-Check-LLP-Announces-Deadline-in-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-AbbVie-Inc.?utm_source=snapi,https://images.financialmodelingprep.com/news/abbv-investor-reminder-kessler-topaz-meltzer-check-llp-announces-20220513.jpg
ABBV,2022-04-29,2022-04-22,2022-05-13,ABBV,,2022-05-13 15:54:00,2022-05-13T15:54:00-04:00,2022-05-13,"ROSEN, RESPECTED INVESTOR COUNSEL, Encourages AbbVie Inc. Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - ABBV","New York, New York--(Newsfile Corp. - May 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August 31, 2021, inclusive (the ""Class Period""), of the important June 6, 2022 lead plaintiff deadline.SO WHAT: If you purchased AbbVie securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...",newsfilecorp.com,https://www.newsfilecorp.com/release/124029/ROSEN-RESPECTED-INVESTOR-COUNSEL-Encourages-AbbVie-Inc.-Investors-With-Losses-Over-100K-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-ABBV?utm_source=snapi,https://images.financialmodelingprep.com/news/rosen-respected-investor-counsel-encourages-abbvie-inc-investors-with-20220513.jpg
